AIMA
PACB icon

Ables Iannone Moore & Associates’s Pacific Biosciences PACB Stock Holding History

Ables Iannone Moore & Associates’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-280
Closed -$2.75K – 225
2023
Q4 		$2.75K Buy
+280
New +$2.29K ﹤0.01% 224

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Ables Iannone Moore & Associates's PACB Position: Q1 2024 in Review

Ables Iannone Moore & Associates sold out of Pacific Biosciences (PACB) in Q1 2024, closing a stake of 280 shares — an estimated $2.75K sold.

Ables Iannone Moore & Associates first reported a position in PACB in Q4 2023 and held it in 1 quarter. The position peaked at $2.75K in Q4 2023. 268 funds tracked by Wall St. Rank hold PACB as of Q1 2024.

  • Ables Iannone Moore & Associates reported no remaining Pacific Biosciences position as of Q1 2024 after selling out during the quarter.
  • Ables Iannone Moore & Associates sold 280 Pacific Biosciences shares in Q1 2024, an estimated $2.75K.
  • Ables Iannone Moore & Associates first reported a position in Pacific Biosciences in Q4 2023 and held it in 1 quarter.
  • Ables Iannone Moore & Associates's Pacific Biosciences position peaked at $2.75K in Q4 2023.
  • 268 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2024.

Based on Ables Iannone Moore & Associates's 13F filing for Q1 2024, filed 30 Apr 2024.